Clarytix is developing a breakthrough oral drug for PTSD that delivers fast-acting, synergistic relief through a novel neuroplastic mechanism. Preclinical trials have shown highly promising results, supporting a strong scientific rationale. Backed by robust IP protection and targeting a huge unmet global need, the drug is positioned for FDA fast-track designation via the 505(b)(2) pathway. We are now advancing toward clinical trials in Israel.